Belzutifan nella malattia di von Hippel-Lindau: il primo inibitore di HIF-2$\alpha $
- 12 August 2026
- journal article
- farmaci innovativi-in-endocrinologia
- Published by Springer Nature in L'Endocrinologo
- Vol. 27 (5) , 585-587
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Belzutifan efficacy in von Hippel-Lindau disease-associated renal cell carcinoma versus natural history control armJNCI: Journal of the National Cancer Institute, 2026
- Belzutifan for patients with Von Hippel-Lindau (VHL) disease-associated heterogeneous tumors – a retrospective single center analysisBMC Cancer, 2025
- Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 studyThe Lancet Oncology, 2025
- FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated TumorsClinical Cancer Research, 2022
- Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau DiseaseNew England Journal of Medicine, 2021